NASDAQ:PRTKParatek Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Paratek Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.07 +0.22 (+5.71 %) (As of 04/7/2020 03:11 PM ET) Add Compare Share Today's Range$3.67Now: $4.07▼$4.1550-Day Range$2.67MA: $3.61▼$4.9752-Week Range$2.50Now: $4.07▼$6.39Volume436,083 shsAverage Volume860,517 shsMarket Capitalization$171.84 millionP/E RatioN/ADividend YieldN/ABeta1.35 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingParatek Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.20, Paratek Pharmaceuticals has a potential upside of 321.6% from its current price of $4.08.Amount of Analyst CoverageParatek Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesParatek Pharmaceuticals has received 409 “outperform” votes. (Add your “outperform” vote.)Underperform VotesParatek Pharmaceuticals has received 366 “underperform” votes. (Add your “underperform” vote.)Community SentimentParatek Pharmaceuticals has received 52.77% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote “Outperform” if you believe PRTK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions54.23% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Paratek Pharmaceuticals are expected to decrease by -53.85% in the coming year, from ($2.47) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.42 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webhttp://www.paratekpharma.com/ Phone617-807-6600Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio9.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$16.54 million Price / Sales10.39 Cash FlowN/A Price / Cash FlowN/A Book Value($1.19) per share Price / Book-3.42Profitability EPS (Most Recent Fiscal Year)($3.93) Net Income$-128,790,000.00 Net Margins-778.47% Return on Equity-5,327.73% Return on Assets-48.93%Miscellaneous Employees101 Outstanding Shares42,220,000Market Cap$171.84 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive PRTK News and Ratings via Email Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PRTK Rates by TradingView Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions How has Paratek Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTK shares have increased by 4.9% and is now trading at $4.08. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Paratek Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Paratek Pharmaceuticals. When is Paratek Pharmaceuticals' next earnings date? Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Paratek Pharmaceuticals. How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals Inc (NASDAQ:PRTK) announced its quarterly earnings data on Tuesday, February, 25th. The specialty pharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.03) by $0.22. The specialty pharmaceutical company had revenue of $8.97 million for the quarter, compared to analyst estimates of $4.78 million. Paratek Pharmaceuticals had a negative net margin of 778.47% and a negative return on equity of 5,327.73%. View Paratek Pharmaceuticals' earnings history. What guidance has Paratek Pharmaceuticals issued on next quarter's earnings? Paratek Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $75-80 million, compared to the consensus revenue estimate of $68.08 million. What price target have analysts set for PRTK? 7 equities research analysts have issued twelve-month target prices for Paratek Pharmaceuticals' shares. Their forecasts range from $6.00 to $36.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $17.20 in the next twelve months. This suggests a possible upside of 321.6% from the stock's current price. View analysts' price targets for Paratek Pharmaceuticals. Has Paratek Pharmaceuticals been receiving favorable news coverage? Headlines about PRTK stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Paratek Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutParatek Pharmaceuticals. Who are some of Paratek Pharmaceuticals' key competitors? Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Pacira Biosciences (PCRX). What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Verastem (VSTM), EXACT Sciences (EXAS), Exelixis (EXEL), Energy Transfer LP Unit (ET), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO). Who are Paratek Pharmaceuticals' key executives? Paratek Pharmaceuticals' management team includes the following people: Mr. Michael F. Bigham, Chairman & CEO (Age 61)Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 60)Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 57)Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 52)Mr. Douglas W. Pagán, Consultant (Age 47) What is Paratek Pharmaceuticals' stock symbol? Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK." How do I buy shares of Paratek Pharmaceuticals? Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Paratek Pharmaceuticals' stock price today? One share of PRTK stock can currently be purchased for approximately $4.08. How big of a company is Paratek Pharmaceuticals? Paratek Pharmaceuticals has a market capitalization of $172.26 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe. View additional information about Paratek Pharmaceuticals. What is Paratek Pharmaceuticals' official website? The official website for Paratek Pharmaceuticals is http://www.paratekpharma.com/. How can I contact Paratek Pharmaceuticals? Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Price-Sales Ratio
